iOnctura

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

Today we are pleased to announce we have dosed our first patient in randomized Phase II study, OCULE-01. OCULE-01 is investigating our allosteric modulator of #PI3Kδ, #roginolisib, in uveal melanoma, a rare cancer of the eye. Allosteric modulation is a new archetype for precise inhibition of PI3Kδ, promising clinical activity without the detrimental tolerability seen with previous generations of inhibitors. In Phase I, roginolisib demonstrated an excellent safety profile and a doubling of overall survival in metastatic uveal melanoma patients compared to historical controls. 👉 Read the press release here: https://lnkd.in/ekMMhJnS 👉Details of the OCULE-01 study: https://lnkd.in/ezQFQVYr

We’ve been at Bio-Europe today, sharing our precision approaches to target neglected and hard-to-treat cancers. Our CEO Catherine Pickering’s panel on the future of oncology was dynamic and engaging and reflected the positive sentiment for the industry in general. Thank you for having us Bio-Europe!

Are you heading to Bio-Europe today? If so, and you would like to learn more about iOnctura and our mission to develop high precision small molecules for neglected and hard-to-treat cancers please reach out. Our CEO Catherine Pickering and Director of Operations Jenny W will be happy to meet you. Catherine is participating in a panel tomorrow on the future of oncology - don't miss it if you are there!

We are pleased to announce today the strengthening of our leadership team with appointments of Elizabeth Holt as Chief Business Officer and Mark Velleca as Board Chair of iOnctura. With a track record of successfully negotiated fundraises, partnerships and exits, Elizabeth most recently co-founded Aiolos Bio Inc, which was acquired by GSK in February 2024 for a total value of $1.4B. She also played a key role in the M&A and BD activities at Gyroscope Therapeutics, which was acquired by Novartis for up to $1.5bn in 2022. Mark is currently the CEO and Board Chair of Black Diamond Therapeutics (BDTX) and also serves as Board Chair of Myeloid Therapeutics. Mark served as CEO of G1 Therapeutics (GTHX) until 2021, when he took the company public and led the development of its first therapy (COSELA®) from IND filing to FDA approval. Mark was a co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. With these appointments we continue to build a world-class leadership team to take iOnctura through into its next phase and beyond. Read the full press release here: 👉 https://lnkd.in/eufDEWq7

🎉Happy International Women’s Day 🎉 The iOnctura team got together this week to strategize, plan and hone our communication skills (thank you Jeremy Grogono!) We are proud of the team we have built and today, on #IWD2025, we celebrate our formidable CEO Catherine Pickering and the two thirds of our team that are female 👏 We wouldn’t be where we are today without these women and we thank each and every one for the value they add and the skills and experience they bring to iOnctura.

We are proud of our #Swiss roots and we were thrilled to represent #Geneva's biotech companies at yesterday's presentation of the 2025-2027 financial plan to foster innovation in the region. Including new physical subsidized space for entrepreneurs, helpful financial incentives, a dynamic ecosystem and supportive initiatives for parents and families, Geneva has considered the needs of emerging biotechs excellently. We look forward to seeing the new ideas and innovations supported by these initiatives in the future.

We are pleased to announce the release of a new Perspectives article on our website. 👏 Coinciding with #RareDiseaseDay last week, we give our perspectives on the most exciting innovations for patients with Uveal Melanoma, a rare cancer of the eye. ➡️ From decision enabling tools such as DecisionDx-UM from Castle Biosciences, Inc. which offers personalized prognostic insights promising better patient care for patients... ➡️ to lab-grown patient-derived organoids, such as those developed by the Mayo Clinic, which provide more accurate models for research... ➡️ to high-precision therapeutics which offer better targeting of key cancer targets whilst minimizing off-target effects to increase patient safety (such as our PI3Kd inhibitor #roginolisib... There are a number of exciting innovations which promise a better future ahead for patients. ☀️ Read the full article here: 👉 https://lnkd.in/e4_7tPSG

It has been wonderful to see the large amounts of coverage for Rare Disease Day 2025, which seeks to raise awareness of rare diseases. Our mission is to develop drugs for rare, neglected, or hard-to-treat cancers. Our Head of Research Giusy Di Conza has been featured in Drug Discovery World's Q&A with industry experts focusing on the landscape and outlook for rare disease research. Read the full article here: 👉 https://lnkd.in/eRAxQ8eP

Rare cancers affect fewer than 6 people per 100,000 each year; however 1 in all 5 cancer cases is rare. The 5 year survival rate is lower for rare cancers. Today, on #rarediseaseday, we highlight our commitment to patients with rare cancers. Our lead compound, #roginolisib, is in development for uveal melanoma, a rare cancer of the eye. It remains central to our mission to develop drugs for rare, neglected, or hard-to-treat cancers. #oncology #orphandrugs #raredisease